Published in P T on August 01, 2015
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer | NCT01057810
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer | NCT01234311
Schizophrenia: overview and treatment options. P T (2014) 1.06
Pharmaceutical Approval Update. P T (2015) 0.80
Pharmaceutical Approval Update. P T (2015) 0.78
Pharmaceutical Approval Update. P T (2015) 0.77
Pharmaceutical approval update. P T (2015) 0.77
Pharmaceutical approval update. P T (2014) 0.77
Pharmaceutical approval update. P T (2015) 0.76
Schizophrenia therapy options increasing. P T (2014) 0.76
Huge growth seen in hepatitis C market. P T (2014) 0.76
Steady progress on Parkinson's disease. P T (2014) 0.75
Sepsis Treatment Options Are Often Lacking. P T (2015) 0.75
Cautious optimism for growth in Alzheimer's disease treatments. P T (2015) 0.75
Diabetes market grows ever more crowded. P T (2014) 0.75
Dyslipidemia: blockbuster therapies are on the horizon. P T (2015) 0.75
Pharmaceutical Approval Update. P T (2015) 0.75
Pharmaceutical approval update. P T (2015) 0.75
Pharmaceutical approval update. P T (2015) 0.75
Ulcerative colitis and Crohn's disease. P T (2014) 0.75
Multiple Sclerosis: Progress, but No Cure. P T (2015) 0.75
Modest growth seen in epilepsy market. P T (2014) 0.75
Pharmaceutical Approval Update. P T (2015) 0.75
Long-Acting Therapies Will Expand Growth Hormone Deficiency Market. P T (2015) 0.75
In the Crowded HIV Market, There's Room for Innovation. P T (2015) 0.75
Pharmaceutical approval update. P T (2015) 0.75
Pharmaceutical approval update. P T (2014) 0.75
Pharmaceutical approval update. P T (2015) 0.75
Pharmaceutical approval update. P T (2014) 0.75